Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2267]

EHA 2022: Dysregulation of RNA binding proteins drive hematopoietic stem cell exhaustion and bone marrow failure

EHA 2022: Dysregulation of RNA binding proteins drive hematopoietic stem cell exhaustion and bone marrow failure

Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional HER3:TRAIL fusion protein

Ellipses Pharma and SunRock Biopharma enter into a licensing agreement for a first-in-class bifunctional...

Tislelizumab plus chemo improved overall survival as first-line treatment for advanced oesophageal cancer in phase III study

Tislelizumab plus chemo improved overall survival as first-line treatment for advanced oesophageal cancer in phase...

Less prostate cancer screening reduces overdiagnosis but may miss aggressive cases

Less prostate cancer screening reduces overdiagnosis but may miss aggressive cases

Illumination of immune checkpoint LAG3 ‘black box’ could yield new cancer and autoimmune therapies

Illumination of immune checkpoint LAG3 ‘black box’ could yield new cancer and autoimmune therapies

NICE recommends tepotinib as the first oral MET inhibitor treatment as an option for adult patients with advanced NSCLC with METex14 skipping alterations

NICE recommends tepotinib as the first oral MET inhibitor treatment as an option for adult patients with advanced...

Using electricity to treat cancer

Using electricity to treat cancer

NICE reverses recommendation allowing use of novel urothelial carcinoma immunotherapy on the NHS

NICE reverses recommendation allowing use of novel urothelial carcinoma immunotherapy on the NHS

The daily life of a sub-Saharan trainee oncologist during the COVID-19 pandemic

The daily life of a sub-Saharan trainee oncologist during the COVID-19 pandemic

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma

FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma

More from ecancer